DNA NANOBOTS, INC.
Programmable, Non-Viral Gene Delivery
Reshaping Gene Therapy™
THE CHALLENGE
Gene Delivery Still Falls Short
Introducing the Genobot
The Genobot is a structurally engineered DNA gene delivery system. By organizing DNA into a defined, programmable scaffold, the gene becomes its own delivery vehicle. Functional elements are precisely positioned, enabling control over biological interaction and therapeutic performance—designed to overcome the payload, dosing, and targeting constraints that limit today’s leading modalities.
Gene Delivery Fails When You Need
Gene Therapy is expensive, inefficient, and is not tissue specific
Vaccines are cell non-specific, leading to suboptimal performance
Chemotherapy drugs have dangerous off-target effects
The Genobot is designed to overcome all three — enabling large-payload delivery, repeat dosing, and programmable targeting from a single structurally defined platform.
DNA isn’t the limitation. The structure is.
OUR PIPELINE
Focused Where Delivery Matters Most
DNA Nanobots is advancing a disease-focused development program built around two indications where current gene delivery falls short. Wilson’s Disease is our pathfinder asset—a liver-accessible disease that aims to validate systemic delivery, large-gene expression, and repeat dosing. Duchenne Muscular Dystrophy (DMD) is our long-term lead objective, requiring delivery of full-length dystrophin that exceeds the payload capacity of AAV.
Partnering to Advance Gene Therapy
DNA Nanobots is seeking strategic biopharma partners and investors who share a vision for next-generation gene delivery. The Genobot platform is being developed to enable applications across a range of delivery-constrained diseases.
Changing the way we delivery therapeutics
Our Expertise
Large Payload Capable
Designed to scale payload without exceeding biologically relevant geometries — enabling delivery of genes too large for AAV, including full-length dystrophin.
Repeat Dose Tolerant
High-dose, repeat administration observed as well tolerated in immunocompetent preclinical models, with liver enzymes remaining within normal ranges.
Programmable by Design
Scaffold geometry and functional ligand placement can be programmed to direct tissue targeting — designed to enable cell-type-specific delivery from a single structurally defined platform.